血管加压素联合甲泼尼龙对院内心搏骤停自主循环恢复的影响:随机临床试验
该多中心随机双盲安慰剂对照试验在丹麦10家医院纳入512例院内心搏骤停成人患者,比较血管加压素联合甲泼尼龙与安慰剂对自主循环恢复的影响。
要点
- 院内心搏骤停时使用血管加压素联合甲泼尼龙可提高自主循环恢复率。
- 该联合治疗未显著改善30天生存率或良好神经功能结局。
- 长期生存获益或危害仍不确定,需进一步研究。
核心结论
- 在院内心搏骤停患者中,与安慰剂相比,血管加压素联合甲泼尼龙显著提高自主循环恢复的可能性。
- 该治疗对长期生存是获益还是危害尚不确定。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验,在丹麦10家医院开展。
- 2018年10月15日至2021年1月21日纳入512例院内心搏骤停成人患者,随机分配至血管加压素联合甲泼尼龙组(n=245)或安慰剂组(n=267)。
- 最终501例符合所有纳入且无排除标准者纳入分析,平均(SD)年龄71(13)岁,男性322例(64%)。
主要发现
- 在实现自主循环恢复的患者中,干预组77例(77%)和安慰剂组63例(73%)发生高血糖;干预组28例(28%)和安慰剂组27例(31%)发生高钠血症。
关键数值与推荐
- 干预措施:首次肾上腺素后给予首剂血管加压素20 IU和甲泼尼龙40 mg或对应安慰剂,每次追加肾上腺素后追加血管加压素或对应安慰剂,最多4剂。
- 主要结局为自主循环恢复;次要结局包括30天生存率和良好神经功能结局(脑功能分类评分1或2)。
临床怎么用
- 对于院内心搏骤停成人患者,可考虑在肾上腺素基础上联合使用血管加压素和甲泼尼龙以提高自主循环恢复率。
- 应向患者及家属说明该治疗对长期生存和神经功能的获益尚不明确。
局限性
- 研究仅纳入丹麦10家医院的患者,外推性需谨慎。
- 长期生存获益或危害的不确定性较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Previous trials have suggested that vasopressin and methylprednisolone administered during in-hospital cardiac arrest might improve outcomes. OBJECTIVE: To determine whether the combination of vasopressin and methylprednisolone administered during in-hospital cardiac arrest improves return of spontaneous circulation. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, double-blind, placebo-controlled trial conducted at 10 hospitals in Denmark. A total of 512 adult patients with in-hospital cardiac arrest were included between October 15, 2018, and January 21, 2021. The last 90-day follow-up was on April 21, 2021. INTERVENTION: Patients were randomized to receive a combination of vasopressin and methylprednisolone (n = 245) or placebo (n = 267). The first dose of vasopressin (20 IU) and methylprednisolone (40 mg), or corresponding placebo, was administered after the first dose of epinephrine. Additional doses of vasopressin or corresponding placebo were administered after each additional dose of epinephrine for a maximum of 4 doses. MAIN OUTCOMES AND MEASURES: The primary outcome was return of spontaneous circulation. Secondary outcomes included survival and favorable neurologic outcome at 30 days (Cerebral Performance Category score of 1 or 2). RESULTS: Among 512 patients who were randomized, 501 met all inclusion and no exclusion criteria and were included in the analysis (mean [SD] age, 71 [13] years; 322 men [64%]). One hundred of 237 patients (42%) in the vasopressin and methylprednisolone group and 86 of 264 patients (33%) in the placebo group achieved return of spontaneous circulation (risk ratio, 1.30 [95% CI, 1.03-1.63]; risk difference, 9.6% [95% CI, 1.1%-18.0%]; P = .03). At 30 days, 23 patients (9.7%) in the intervention group and 31 patients (12%) in the placebo group were alive (risk ratio, 0.83 [95% CI, 0.50-1.37]; risk difference: -2.0% [95% CI, -7.5% to 3.5%]; P = .48). A favorable neurologic outcome was observed in 18 patients (7.6%) in the intervention group and 20 patients (7.6%) in the placebo group at 30 days (risk ratio, 1.00 [95% CI, 0.55-1.83]; risk difference, 0.0% [95% CI, -4.7% to 4.9%]; P > .99). In patients with return of spontaneous circulation, hyperglycemia occurred in 77 (77%) in the intervention group and 63 (73%) in the placebo group. Hypernatremia occurred in 28 (28%) and 27 (31%), in the intervention and placebo groups, respectively. CONCLUSIONS AND RELEVANCE: Among patients with in-hospital cardiac arrest, administration of vasopressin and methylprednisolone, compared with placebo, significantly increased the likelihood of return of spontaneous circulation. However, there is uncertainty whether this treatment results in benefit or harm for long-term survival. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03640949.
引用
- Andersen LW, Isbye D, Kjærgaard J, et al. Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2021. PMID: 34587236. doi:10.1001/jama.2021.16628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。